Author

María Pilar Arenaz-Callao

Fundacion Agencia Aragonesa para la Investigacion y el DesarrolloORCID 0009-0000-4852-6130Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 1

Frequent Co-Authors

Alfonso Mendoza-LosanaiD· 2 shared Rubén González del Río· 2 shared Santiago Ramón‐GarcíaiD· 2 shared Ángel Santos-Villarejo· 1 shared Charles J. ThompsoniD· 1 shared David Barros-AguirreiD· 1 shared Esther Pérez‐HerrániD· 1 shared Esther Porras de FranciscoiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Alfonso Mendoza-LosanaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintMay 10, 2026

OPTIKA, a new high content kill-kinetic assay to longitudinally assess in vitro drug combinations against Mycobacterium tuberculosis

María Pilar Arenaz-Callao, Pablo Gamallo, Alfonso Mendoza-Losana…·Santiago Ramón‐García

The paper introduces OPTIKA, a high-throughput time-kill assay for assessing drug combinations against Mycobacterium tuberculosis, showing it outperforms traditional methods by over 1000-fold.

DOI 10.64898/2026.05.10.724062

experimental assaydrug response / drug discovery

𝕏 PostBluesky

MicrobiologyDrug Resistance UpdatesPeer-reviewedFeb 15, 2025

Sanfetrinem, an oral beta-lactam antibiotic repurposed for the treatment of tuberculosis

Santiago Ramón‐García, Rubén González del Río, María Pilar Arenaz-Callao…·Robert H. Bates

This paper identifies sanfetrinem cilexetil as a promising oral beta-lactam antibiotic for tuberculosis treatment through preclinical studies showing its activity against Mtb and potential for repurposing.

10 citationstop 3%

humanexperimental assay

𝕏 PostBluesky